Genomic diversity and antimicrobial resistance of Prevotella species isolated from chronic lung disease airways

Kasey A. Webb1,2, Olusola Olagoke1,2, Timothy Baird2,3, Jane Neill3, Amy Pham4, Timothy J. Wells4, Kay A. Ramsay5‡, Scott C. Bell5,6,7, Derek S. Sarovich1,2,*,† and Erin P. Price1,2,*,†

Abstract
Cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) are characterized by increasingly frequent acute pulmonary exacerbations that reduce life quality and length. Human airways are home to a rich polymicrobial environment, which includes members of the obligately anaerobic genus Prevotella. Despite their commonness, surprisingly little is known about the prevalence, role, genomic diversity and antimicrobial resistance (AMR) potential of Prevotella species and strains in healthy and diseased airways. Here, we used comparative genomics to develop a real-time PCR assay to permit rapid Prevotella species identification and quantification from cultures and clinical specimens. Assay specificity was validated across a panel of Prevotella and non-Prevotella species, followed by PCR screening of CF and COPD respiratory-derived cultures. Next, 35 PCR-positive isolates were subjected to whole-genome sequencing. Of eight identified Prevotella species, P. histicola, P. melaninogenica, P. nanceiensis, P. salivae and P. denticola overlapped between participant cohorts. Phylogenomic analysis revealed considerable interhost but limited intrahost diversity, suggesting patient-specific lineages in the lower airways, probably from oral cavity aspirations. Correlation of phenotypic AMR profiles with AMR genes identified excellent correlation between tetQ presence and decreased doxycycline susceptibility, and ermF presence and decreased azithromycin susceptibility and clindamycin resistance. AMR rates were higher in the CF isolates, reflecting greater antibiotic use in this cohort. All tested Prevotella isolates were tobramycin-resistant, providing a potential selection method to improve Prevotella culture retrieval rates. Our addition of 35 airway-derived Prevotella genomes to public databases will enhance ongoing efforts to unravel the role of this diverse and enigmatic genus in both diseased and healthy lungs.

DATA SUMMARY
Thirty-five Prevotella genomes generated in this study are available in the Sequence Read Archive (SRA) and GenBank databases under BioProject accession PRJNA742126.

INTRODUCTION
Chronic lung diseases are a leading cause of global healthcare burden and early mortality [1, 2]. Although cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) have fundamentally different aetiologies, both are characterized by impaired airway mucociliary clearance, which provides a favourable environment for microbial colonization and persistence, and a challenging...
Impact Statement

*Prevotella* are common and abundant obligate anaerobes found throughout the human body, including airways. Despite their commonness, accurate speciation of respiratory *Prevotella* remains challenging, with many microbiome studies reporting results only to the genus level. Here, we whole-genome-sequenced 35 *Prevotella* strains isolated from cystic fibrosis and chronic obstructive pulmonary disease airways to improve representation of airway-derived *Prevotella* species in public databases, and in turn, the speciation performance of meta-omics software. Using comparative genomics, we next designed a highly specific *Prevotella* PCR assay to permit accurate *Prevotella* identification from isolates and clinical specimens, undertook phylogenomic analysis to better understand *Prevotella* diversity and within-host evolution, and correlated phenotypes towards 11 clinically relevant antibiotics with presence of antimicrobial resistance (AMR) genes. *ermF* presence largely predicted decreased susceptibility or resistance towards azithromycin and clindamycin; similarly, *tetQ* presence provided excellent prediction of doxycycline non-susceptibility. All isolates were resistant towards tobramycin, an antibiotic commonly used to treat cystic fibrosis airway exacerbations. We observed dramatic phenotypic differences in pigment-producing *Prevotella* species according to growth medium, demonstrating the essentiality of molecular characterization for accurate speciation. Our study provides important new insights into the microbiology, diversity, prevalence, AMR potential, evolution and origin of *Prevotella* species found in diseased airways.

Environment for pathogen eradication. Infections are the primary contributor in CF and COPD respiratory exacerbations (i.e. acute worsening of symptoms), during which inflammation and irreversible airway damage can occur [3]. In CF, 80–95% of deaths are associated with acute exacerbations and chronic bacterial infections, which eventually lead to respiratory failure [4]. In COPD, bacterial, viral and fungal respiratory infections trigger ~70–80% of exacerbation events [5]. Despite their crucial role in reducing quality and length of life, there remain major gaps in understanding the collective microbial drivers associated with CF and COPD pathophysiology.

Routine culture-based diagnosis of CF and COPD exacerbations often overlooks more fastidious or uncultivable members within the airway microbiome, leaving a gap in fully understanding the complex composition and activity of CF and COPD microbiomes [6, 7]. Culture-independent techniques such as mettaxonomics (e.g. 16S rRNA amplicon sequencing), metagenomics and metatranscriptomics are gaining traction as adjuncts or potentially even alternatives to culture due to their ability to identify a much broader spectrum of microbes, including uncultured taxa, resulting in better diagnosis, more informed treatment strategies and improved clinical outcomes [8–10]. In addition to identifying well-characterized microbes associated with respiratory exacerbations, molecular methods have unveiled previously unidentified microbial communities in chronic lung disease airways, including a diverse anaerobic microbiome [11].

The genus *Prevotella*, which comprises ≥51 species [12, 13], is a common and often abundant obligate anaerobe in the human body, including in CF and COPD airways [11, 14–19]. Despite its commonness, the role of *Prevotella* in disease progression is incompletely understood in CF [11], and even less so in COPD. Several studies investigating *Prevotella* species in airway disease, particularly CF, have yielded conflicting evidence. Some studies suggest a likely pathogenic role [18, 20], whereas others have shown no role [21], or even a benefit when *Prevotella* species are abundant [22, 23]. A major contributor to these equivocal findings is that culture-dependent and metatranscriptomic methods largely fail to identify microbes to the species and strain level [7, 13, 24, 25]. As such, only a handful of *Prevotella* studies have described potential species- or strain-specific mechanisms in airway disease pathogenesis.

The number of *Prevotella* genomes has been steadily increasing in recent years. However, in comparison to more intensely studied CF and COPD airway organisms, there is a relative paucity of respiratory *Prevotella* genomic data in public databases. Most *Prevotella* species contain only a single representative (and many were generated from a single metagenomic study) [26], leading to issues with correct species assignments from metagenome-assembled genomes. Further, most genomic studies have concentrated on known *Prevotella* pathogens in oral (e.g. *P. intermedia* and *P. nigrescens*), gut (e.g. *P. copri*) and urogenital (e.g. *P. bivia*) microbiomes [27–29]. There is a lack of knowledge about the *Prevotella* species commonly found in airways, particularly in COPD. Insufficient resolution to the species and strain level has limited our understanding of *Prevotella* species diversity, function, evolution and antimicrobial resistance (AMR) potential within CF and COPD airways during exacerbations and stability [13, 24].

Here, we first used a comparative genomics approach to design and optimise a novel real-time PCR assay to permit the rapid, cost-effective and specific detection of *Prevotella* species from both culture and clinical specimens. Next, 57 CF-COPD sputa and 12 COPD bronchial washings were cultured to isolate individual *Prevotella* strains for whole-genome sequencing (WGS) characterization, followed by genomic analyses to determine species identity, strain relatedness and within-host evolution. Cultured isolates were subject to AMR testing across 11 clinically relevant antibiotics, and correlated with AMR determinants identified by WGS. Finally, *Prevotella* morphological characteristics were assessed for their diagnostic value.
METHODS

Sample collection and storage

A total of 36 CF sputa were obtained from 21 expectorating adults with CF presenting at The Prince Charles Hospital (TPCH) Adult CF Centre between 2017 and 2019. Seven participants provided multiple sequential sputa (Table S1, available in the online version of this article). Sputa were stored non-an aerobically at −80 °C in Luria–Bertani broth containing 20% glycerol, and stored for 2–24 months prior to microbiological assessment. A total of 33 COPD sputa (n=21) or bronchial washings (BWs; n=12) were obtained from 21 current/former tobacco smokers during community or in-hospital consult at Sunshine Coast Hospital and Health Service in 2020 (Table S1). Five participants provided multiple sequential sputa (Table S1). BWs were taken from participants with suspected lung cancer, with most collected as paired specimens from both the tumour site (biopsied after BW collection) and approximately the same position in the non-tumour contralateral lung. BWs were pelleted at 4 °C and ~9300 x g for 15 min, with supernatant removed and pellet resuspended in 800 µl PBS. COPD samples were stored within 12–36 h of collection using the same parameters as described for the CF sputa, and microbiologically processed within ~2 weeks of collection. Clinical and antibiotic treatment regimens were recorded (Table S1) to permit correlation with Prevotella AMR profiles.

Microbiological preparation and storage

Clinical samples were directly subcultured onto anaerobic blood medium containing nalidixic acid and vancomycin (Thermo Fisher Scientific; cat. no. PP2065). Plates were incubated anaerobically at 37°C in an AnaeroPack 2.5-litre jar with an AnaeroGen 2.5-litre gas pack (Thermo Fisher) for 2–5 days. Isolates were subcultured based on different morphotypes, with a second subculture for purity onto non-selective anaerobic blood medium (Thermo Fisher; cat. no. PP2039). Prevotella real-time PCR-positive isolates were again sub-cultured onto non-selective anaerobic blood medium for purity and stored non-an aerobically at −80 °C in 1 ml Luria–Bertani broth containing 20% glycerol. Additionally, WGS-confirmed, representative Prevotella isolates derived from CF samples were cultured from glycerol stocks onto both polyvitaminic-supplemented chocolate agar (PVCA; Edwards Group; cat. no. 1065) and non-selective anaerobic blood medium to assess phenotypic differences over a 10-day period.

DNA extractions

DNA of presumptive Prevotella isolates was initially extracted using 5% chelex-100 [30] (Bio-Rad), heat-treated at 95°C for 20 min, and diluted to 1:50 with molecular-grade H₂O prior to PCR. DNA for WGS was extracted using the NanoDrop 2000 spectrophotometer (Thermo Fisher).

Clinical specimens were extracted using three parts TRI Reagent LS (Sigma-Aldrich) to one part specimen, 30 µl 0.1 M 2-mercaptoethanol, and ~100 µl equal mixture of 0.1 and 0.5 mm zirconia beads (Daintree Scientific). Homogenization comprised eight rounds of 30 s bead beating (each round followed by 30–60 s on wet ice) using the ‘medium’ setting of the Minilys tissue homogenizer (Bertin Instruments). After removal of the RNA aqueous phase, back extraction was performed on the interphase and proteinaceous phase [31] to isolate total DNA.

Prevotella species real-time PCR assay design

Due to high levels of genetic variability among Prevotella species, the highly conserved 16S–23S rRNA genes were targeted. A BLAST32 2.10.2+ database was created using 60 Prevotella genomes encompassing 26 assigned and nine unassigned species (Table S2). Discontiguous MegaBLAST was carried out against the 4.8 kb P. intermedia ATCC 25611 23S–16S rRNA locus (GenBank accession CP019300.1, coordinates 63001–67800) using the BLAST database. BLAST_xml outputs were aligned and visualized using Geneious Prime vR10. A highly conserved area within the Prevotella 16S rRNA gene was assessed further to identify potential PCR oligos, with conserved regions possessing several SNPs in other microbes exploited during probe and primer design. Primers and probes were initially assessed using Primer Express v3.0 (Applied Biosystems) to test melting temperature (Tm) suitability in Black Hole Quencher format (primer Tm=60°C; probe Tm=70°C). All candidate primers and probes were assessed for self- and hetero-dimer formation using Beacon Designer (http://www.premierbiosoft.com/qpcr/), with oligo sequences requiring a ΔG value of >−4 kcal mol⁻¹. Candidate oligos were subsequently subjected to NCBI Microbial Nucleotide BLAST and Nucleotide BLAST searches to confirm specificity for Prevotella species. As the 16S region is highly conserved in all bacteria, the forward primer incorporated a penultimate mismatch to prevent non-specific binding to closely related non-Prevotella taxa. Additionally, a BHQplus probe (CAL Fluor Gold 540-pdCApdUpdUpdCGApdCGGGGpUGG-BHQ1; Biosearch Technologies) was included to enhance specificity and to permit assay use on clinical specimens. Forward (5’-TTTCCAGtCCAGATGTGtC-3’) and reverse (5’-CGGGGATAACAGGCTGATCC-3’) primers were manufactured by Macrogen, with lowercase nucleotides representing intentional mismatches.

Real-time PCRs were carried out on a Bio-Rad CFX96 thermocycler using 0.35 µM primers and probe, 1× Sso Advanced Universal mastermix (Bio-Rad), molecular-grade H₂O, and 1 µl template, to a 5 µl final volume. Thermocycling parameters were: 95 °C for 2 min, followed by 45 cycles of 95°C for 5 s and 60°C for 20 s. DNA integrity for all clinical samples was assessed via amplification
towards β-globin [33] (human) and universal 16S rRNA [34] (bacteria); the universal 16S rRNA assay was also used to verify bacterial culture DNA integrity, and a panfungal assay (O. Olagoke and E. Price, unpublished) was used to verify Candida species DNA integrity.

**Real-time PCR assay optimization and specificity testing**

The final optimized real-time PCR assay was assessed for accuracy by running against a diversity panel of six *Prevotella* species (one each of *P. copri*, *P. denticola*, *P. histicola*, *P. melaninogenica*, *P. nigrescens* and *P. salivae*), one human DNA sample, and 40 non-*Prevotella* species, with a focus on common respiratory tract microbes (*n*=1 unless otherwise stated): *Achromobacter xylosoxidans*, *Bordetella bronchiseptica*, *Burkholderia cepacia*, *Burkholderia territorii*, *Burkholderia thailandensis*, *Candida albicans*, *Candida dubliniensis*, *Capriavidus metallidurans*, *Enterobacter aerogenes*, *Enterobacter cloacae* (*n*=3), *Enterooccus raffinosus*, *Klebsiella oxytoca*, *Klebsiella pneumoniae* (*n*=2), *Lactocaseibacillus paracasei* (*n*=2), *Pseudomonas aeruginosa* (*n*=12), *Staphylococcus aureus* (*n*=3), *Staphylococcus haemolyticus*, *Stenotrophomonas maltophilia*, *Veillonella atypica* (*n*=3), *Veillonella parvula* and *Veillonella dispar*. All DNA was normalized spectrophotometrically to 2 ng µl⁻¹ prior to PCR.

Limits of detection (LoD) and quantification (LoQ) for the optimized assay were determined with *P. melaninogenica* LMG 28911 DNA, using serial dilutions of 4 ng µl⁻¹ to 4×10⁻⁶ ng µl⁻¹ across eight replicates per dilution. The upper and lower LoD/LoQ limits were determined as described elsewhere [35]. Genome equivalence was determined based on an average *Prevotella* genome size of 3.29 Mbp (based on 894 *Prevotella* genomes, as at 23 August 2021) and four copies of the 16S rRNA gene.

**16S rRNA gene diversity profiling (metataxonomics)**

Metataxonomics was performed by the Australian Genome Research Facility (AGRF) for total CF DNA and ID Genomics for total COPD DNA using standard protocols for V3–V4 (i.e. 341F and 806R) primers.

**Antimicrobial resistance profiling**

Twenty-eight glycerol-stocked *Prevotella* cultures were subcultured onto non-selective anaerobic blood medium, or PVCA where no growth was obtained on the anaerobic medium (*n*=2), and incubated at 37°C under anaerobic conditions for 2–3 days. Cultures were then resuspended in PBS to an OD₆₀₀ of 0.75 (Biochrom). Six supplemented chocolate plates per isolate were lawn-inoculated with the OD-normalized cells as previously described [36], and antibiotic discs (Edwards Group) towards 11 antibiotics [amoxicillin-clavulanate (AMC) 30 µg; azithromycin (AZM) 15 µg; ceftazidime (CAZ) 30 µg; chloramphenicol (CHL) 30 µg; clindamycin (CLI) 2 µg; doxycycline (DOX) 30 µg; imipenem (IPM) 30 µg; meropenem (MEM) 10 µg; metronidazole (MZ) 5 µg; piperacillin-tazobactam (TZP) P:100 µg, TZ:10 µg; tobramycin (TOB) 10 µg] were placed onto inoculated plates. Plates were incubated at 37°C under anaerobic conditions for 48 h prior to measurement. As no disc diffusion reference ranges exist for *Prevotella* species, growth up to the disc (i.e. 6 mm diameter) was denoted as AMR, which underestimates the true rate of AMR but provides a clear cut-off for unambiguous interpretation. Diameters ≤30 mm for any antibiotic were denoted as reduced susceptibility.

**Whole-genome sequencing**

PCR-confirmed *Prevotella* isolates were sequenced using the Illumina HiSeq 2500 platform with 150 bp seqWell plexWell paired-end read chemistry at AGRF.

**Genome assemblies**

*Prevotella* genomes were *de novo* assembled using default Microbial Genome Assembly Pipeline v1.1 (https://github.com/dsarov/MGAP---Microbial-Genome-Assembler-Pipeline) or SPAdes [37] parameters.

**Speciation and mixture analysis**

*Prevotella* assemblies were initially assessed for species identification and mixtures using the Ribosomal MLST [38] tool. Isolates containing mixtures of *Prevotella* and non-*Prevotella* species (*n*=8), or multiple *Prevotella* species (*n*=1) (Table S3), were excluded from further investigation.

**Phylogenetic analysis**

We initially attempted phylogenomic analysis of *Prevotella* species using a variant-calling approach [39]; however, we encountered insufficient Illumina read mapping using the default BWA-MEM [40] aligner due to extensive sequence diversity amongst taxa. To combat this issue, we instead created a BLAST 2.10.2+ database of *Prevotella* genomes (*n*=234) comprising taxa of known (*n*=56) and unassigned (*n*=40) species, and including non-mixed isolate genomes sequenced in this study (*n*=35 genomes). BLAST analysis was performed against the full-length 1534 bp *P. melaninogenica* 16S rRNA gene (RefSeq ID: NC_014371.1; bases 962784–964317). Hits were filtered to remove redundancies (final *n*=199), and reads were aligned
using ClustalX2 v2.1 [41]. A dendogram was reconstructed using the neighbour-joining method and the Tamura–Nei model and viewed in FigTree v1.4.0 (http://tree.bio.ed.ac.uk/software/figtree/) using midpoint rooting.

**Phylogenomics**
Within-species variant identification of our CF-COPD genomes (‘SCHI’ prefix) was performed using SPANDx v4.0 [39]. Reference genomes for *P. denticola*, *P. histicola*, *P. melaninogenica*, *P. nanceiensis* and *P. saliva* were downloaded from GenBank (IDs GCA_000193395.1, GCA_018128125.1, GCA_000144405.1, GCA_000163055.2 and GCA_000477535.1, respectively) and used for read mapping. Synthetic 150 bp, paired-end Illumina reads at 20× depth and an -m of 200 were generated from GenBank genome assemblies for *P. denticola* (GCA_000191765.2, GCA_000759205.1, GCA_000421205.1, GCA_003515045.1 and GCA_900454835.1), *P. histicola* (GCA_000613925.1), *P. melaninogenica* (GCA_000163035.1, GCA_000759305.1, GCA_002208725.2, GCA_003609775.1 and GCF_000517825.1), *P. nanceiensis* (GCA_000517825.1 and GCA_000613985.1) and *P. saliva* (GCA_000185845.1 and GCA_902374235.1) using ART v2.3.7 [42]. Illumina reads for *P. histicola* T05-04T (SRR1518629) and *P. melaninogenica* ADL403 (SRR755359) were downloaded from the Sequence Read Archive database and quality filtered using Trimmomatic v0.39 [43] parameters described elsewhere [44]. The resulting biallelic, orthologous SNP matrix generated by SPANDx was phylogenetically reconstructed using the maximum-parsimony heuristic function of PAUP* v4.0a (build 168). Bootstrapping was performed in PAUP using 1000 replicates. Phylogenies were visualized in FigTree v1.4.0.

**AMR determinant analysis**
The Resistance Gene Identifier v5.1.1, which employs the Comprehensive Antibiotic Resistance Database (CARD) v3.1.0 [45], was used to identify putative AMR determinants.

**RESULTS AND DISCUSSION**
Molecular typing approaches have been instrumental in unveiling previously untapped microbial diversity in both healthy and diseased lungs. Using these techniques, *Prevotella* have consistently been identified as one of the most prevalent taxa in CF and COPD airways [10, 14, 19]. However, most studies to date have employed 16S metatranomics (usually targeting the V3–V4 gene region), which only characterizes *Prevotella* to the genus level, despite species and strain resolution being fundamental to unravelling the role of these anaerobes in chronic lung disease. To address this knowledge gap, our study used a combination of culture-dependent and culture-independent methods to examine the genomic and phenotypic diversity, and prevalence, of *Prevotella* species present in CF and COPD airways.

We first used a comparative genomics-guided approach to develop an accurate real-time PCR assay for the rapid detection of *Prevotella* species, to the exclusion of all other organisms, both from cultures and clinical specimens. Our PCR assay was reasonably sensitive, with LoD and LoQ both being 400 fg µl⁻¹, or 444 genome equivalents (Fig. 1). When tested against a diverse panel
DNA levels were below the PCR LoD threshold. Thus, culture-independent methods are highly suitable for accurate identification of some strains residing in the oral cavity and oropharynx. Detailed analysis showed that Prevotella species are common habitats for CF and COPD, except Prevotella nigrescens and P. jejuni, which are unique to COPD. One explanation for this overlap is that the CF and COPD microbiota may share similar species, despite being fundamentally different diseases. There was little difference in species prevalence between CF and COPD, except Prevotella species. WGS identified six species: P. salivae, P. buccae, P. denticola, P. nigrescens, P. melaninogenica, and P. histicola. Among the 18 isolates, WGS and phylogenetic analysis on cultured isolates identified seven Prevotella species: P. histicola (n=5), P. melaninogenica (n=5), P. denticola (n=3), P. nanceiensis (n=2), P. jejuni (n=1), P. nigrescens (n=1), and P. salivae (n=1). This approach robustly differentiated Prevotella species, demonstrating that full-length 16S rRNA gene sequencing can be used to accurately speciate members of this genus.

| Table 1. Prevotella species prevalence in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) according to microbiological culture, real-time PCR and 16S rRNA gene metataxonomics |
|---------------------------------|----------------|----------------|
| Prevotella+ve                      | CF             | COPD           |
|---------------------------------|----------------|----------------|
| Participants | Culture | 11/21 (52%) | 6/21 (29%) |
| Specimens | PCR | 17/21 (81%) | 15/21 (71%) |
| Metataxonomics | Culture | 15/17 (88%) | 16/18 (89%) |
| PCR | 16/36 (44%) | 9/32 (28%) |
| Metataxonomics | 29/36 (81%) | 21/32 (66%) |
| Metataxonomics | 26/31 (84%) | 20/22 (91%) |

of 47 microbial and human DNA, the PCR demonstrated 100% specificity, amplifying all six tested Prevotella species, but none of the non-Prevotella species DNA and 10 no-template controls. On clinical specimens, the PCR identified Prevotella in 81% CF and 71% COPD participants, and in 81% CF and 66% COPD specimens (Table 1). This difference in detection rates between diseases was expected given the generally lower total bacterial load in COPD airways [1]. Metataxonomics had higher Prevotella sensitivity than PCR, identifying Prevotella in six PCR-negative samples, although there was one false-negative (SCH10049.C.3, which was PCR- and culture-positive); there was otherwise near-perfect correlation between PCR and metataxonomics (Table S3). In the six PCR-negative samples, Prevotella relative abundance was very low (0.004–0.3%; median=0.05%), indicating that DNA levels were below the PCR LoD threshold. Thus, culture-independent methods are highly suitable for accurate detection of Prevotella from polymicrobial specimens, particularly real-time PCR, which is often performed upon clinical sample receipt, thereby permitting same-day detection of Prevotella in respiratory samples.

Culture of sputa and BWs onto three different agars (anaerobic blood medium containing nalidixic acid and vancomycin, non-selective anaerobic blood medium and PVCA) yielded a much lower Prevotella positivity rate compared with PCR and metataxonomics. Only 44% CF and 28% COPD clinical specimens were Prevotella-positive via culture, compared with 81 and 66% using PCR, and 84 and 91% using metataxonomics (Table 1). The reduced retrieval rate in COPD vs. CF can be explained by lower relative Prevotella abundance according to metataxonomics [0.3–74.3% (median=9.6%) for CF vs. 0.002–36.4% (median=0.6%) for COPD]. The lower prevalence of Prevotella using culture is probably due to multiple factors, such as an inability of culture-independent methods to distinguish viable from non-viable cells, nutritional fastidiousness, cells being in a viable but non-culturable state, and outcompetition from faster-growing taxa [9, 19, 22]. A prior study found that four different culture media were required to recover 42 Prevotella isolates from 26 samples, and only 20 isolates were recoverable on more than one medium [19]. Moreover, all four media were required to recover P. melaninogenica from all sputum samples [19], suggesting that growth requirements may be species- and strain-specific. In contrast to this prior work, we used aerobic collection and storage conditions, which probably precluded recovery of Prevotella taxa with poor/no aerotolerance [46]. Consistent with their fastidiousness, one P. histicola and five P. melaninogenica initially isolated in our study were unable to be resuscitated from glycerol stocks upon repeated attempts, despite previously being cultureable. Taken together, it is probable that several Prevotella species or strains were not recovered by culture in our study due to multiple factors, thereby underestimating species and strain diversity within our cohorts.

To gain greater insight into Prevotella residing in CF and COPD airways, we performed WGS and phylogenetic analysis on cultured isolates to determine species identity and strain relatedness. From 36 CF sputa, 27 PCR-positive Prevotella colonies were recovered, of which 18 were pure Prevotella species; the remaining nine contained a mixture of Prevotella and other taxa, or a mixture of multiple Prevotella species, due to insufficient subculturing for purity prior to WGS (Table S3). To avoid known bioinformatic analysis issues associated with variant calling from mixtures [47], these mixed data were excluded from phylogenetic analysis. Among the 18 isolates, WGS followed by phylogenetic reconstruction using the full-length 16S rRNA gene identified seven Prevotella species: P. histicola (n=5), P. melaninogenica (n=5), P. denticola (n=3), P. nanceiensis (n=2), P. jejuni (n=1), P. nigrescens (n=1) and P. salivae (n=1) (Fig. 2). This approach robustly differentiated Prevotella species (Fig. 2), demonstrating that full-length 16S rRNA gene sequencing can be used to accurately speciate members of this genus. Of the 17 COPD-derived isolates, none were mixed due to a greater number of passages carried out to obtain purity (Table S3). WGS identified six Prevotella species: P. melaninogenica (n=8), P. histicola (n=3), P. salivae (n=3), P. buccae (n=1), P. denticola (n=1) and P. nanceiensis (n=1) (Fig. 2). Despite being fundamentally different diseases, there was little difference in Prevotella species found in CF and COPD, with only P. jejuni and P. nigrescens being unique to CF, and P. buccae being unique to COPD. One explanation for this overlap is that the oral cavity and oropharynx are common habitats for all retrieved species, except P. jejuni [48]; it is thus possible that some strains we isolated were upper airway residents. Whilst oral cavity contamination is unavoidable during respiratory secretion collection, especially for sputum, microbes can also enter lower airways via small-volume oral cavity aspirations; indeed, the risk of microbial colonization and persistence is greatly increased in mucociliary-impaired CF and COPD airways [24, 49–53]. In support of lower airway origin, we identified Prevotella species in both sputa and BWs. Unlike sputa, BWs are collected via bronchoscopy and thus

---

**Table 1.** Prevotella species prevalence in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) according to microbiological culture, real-time PCR and 16S rRNA gene metataxonomics

| Prevotella+ve | CF | COPD |
|--------------|----|------|
| Participants | Culture | 11/21 (52%) | 6/21 (29%) |
| Specimens | PCR | 17/21 (81%) | 15/21 (71%) |
| Metataxonomics | Culture | 15/17 (88%) | 16/18 (89%) |
| PCR | 16/36 (44%) | 9/32 (28%) |
| Metataxonomics | 29/36 (81%) | 21/32 (66%) |
| Metataxonomics | 26/31 (84%) | 20/22 (91%) |

---

**Webb et al., Microbial Genomics 2022;8:000754**

---

6
are far less prone to oral/oropharynx contamination, providing greater confidence that many of our retrieved *Prevotella* isolates originated from the lower airways.

The origin of *P. jejuni* in one CF participant is somewhat perplexing. This species was first documented in the small intestine of a child with coeliac disease in 2012 [54], and little is currently known about the distribution of this organism in healthy and diseased niches; just one prior study has described this organism in the oral cavity based on partial (550 bp) 16S rRNA gene sequencing [55]. Although the oral cavity is the probable origin of this organism in our CF participant, another possibility is that *P. jejuni* entered the CF airways via inhalation of gastro-oesophageal aspirations. Alternatively, microbial inter-compartment

---

**Fig. 2.** Full-length 16S rRNA gene phylogenetic analysis of the 35 *Prevotella* strains retrieved in this study (identified by ‘SCHI’ prefix) against 199 non-redundant public *Prevotella* genomes comprising 56 taxa of known species and 40 taxa of unassigned species. Species clades containing isolates identified from our cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) specimens are coloured. No. nucleotide substitutions per site.
cross-talk between the lungs and gut (the ‘Gut–Lung axis’) via the mesenteric lymphatic system may explain its presence in the lungs [56]. As a relatively new taxon, little is known about possible mechanisms of P. jejuni pathogenesis, with more work needed to determine the prevalence and virulence potential of this bacterium in both healthy and diseased airways.

The most frequently isolated Prevotella species in our study – P. melaninogenica (37%), P. histicola (23%), P. salivae (11%), P. denticola (11%) and P. nanceiensis (9%) – are common in CF [14, 15, 19] and COPD [25] airways. However, their precise role in airway disease is poorly understood due to conflicting reports about their beneficial vs. pathogenic potential. For instance, P. melaninogenica, P. salivae and P. nanceiensis may inhibit non-typeable Haemophilus influenzae-induced pro-inflammatory cytokine production by lung dendritic cells [53], increased P. melaninogenica prevalence in CF airways has been associated with improved lung function [15], and P. histicola can mute pro-inflammatory pathways triggered by P. aeruginosa in CF airways [57]. In contrast, P. melaninogenica produced the greatest variety of short-chain fatty acids (associated with inflammation) amongst five tested anaerobes [18], and P. denticola shares similarities in its lipid A moieties to P. intermedia (a known pathogenic species), pointing towards pro-inflammatory traits [58]. Finally, certain strains of the periodontal disease-associated species, P. nigrescens, a close relative of P. intermedia, are thought to encode an enzymatic cell hydrolysis mechanism that destroys tissues. Given the reported conflicting roles of Prevotella species in chronic lung disease, these collective results suggest that virulence mechanisms vary among Prevotella strains, which requires further exploration [59, 60]. Our genomic data will assist these future efforts.

In our experience, metagenomic analysis tools can struggle with Prevotella species-level identification from respiratory specimens due to a lack of accurate representative species in public databases. Exemplifying this problem, few publicly available genomic data are available for P. nanceiensis – only three were available at the time this study was undertaken, one of which is misclassified as P. melaninogenica, and another as Prevotella sp. (Fig. 3). Thus, our addition of three P. nanceiensis genomes doubles the available P. nanceiensis data. Similarly, there are currently only a handful of non-redundant P. jejuni genomes in public databases, and none are from lower airway specimens; our addition P. jejuni SCHI0011.S.13 genome is therefore valuable for future respiratory and gastroenterological studies. Taken together, our P. nanceiensis and P. jejuni genomes will help public database curation efforts, and in turn improve species identification using metagenomics.

To determine strain relatedness within and between participant airways, we undertook within-species analyses of our P. denticola, P. histicola, P. melaninogenica and P. salivae genomes (Fig. 3; see Fig. S1 for phylogenies rooted with near-neighbour taxa). Whole-genome SNP analysis revealed high levels of strain and interhost diversity in all examined Prevotella species. For example, genetic variation was as high as ~72 000 SNPs among P. histicola strains, an impressive feat for an organism encoding a 3 Mbp genome, and P. nanceiensis strains SCHI0010.S.3 and SCHI0011.S.12 were more closely related to strains isolated from France and the USA, respectively, than to other strains retrieved from other Australian participants. In contrast, intrahost diversity was relatively limited (0–297 SNPs), with two instances of genetically indistinguishable strains: P. histicola SCHI0034.S.5 and SCHI0034.S.6, and P. melaninogenica SCHI0034.S.7 and SCHI0034.S.9 (Fig. 3). The P. histicola pair were retrieved from the same contralateral lung BW, and the P. melaninogenica pair were retrieved from a BW and sputum collected on the same day (Tables S1 and S3). The only exception was P. melaninogenica from SCHI0007, where two genetically distinct lineages separated by >20 000 SNPs were retrieved from this participant. There was no evidence of genetically related strains among any of the Australian participants for any Prevotella species (Fig. 3). These findings indicate that interhost diversity is very high, whereas within-host Prevotella diversity is limited, possibly due to frequent microaspiration of Prevotella from upper to lower airways (or via the gut–lung axis) rather than chronic infection; however, more in-depth sampling is required to investigate Prevotella persistence. Antibiotics are routinely used in the maintenance and treatment of acute respiratory infections in CF and COPD [15, 61]. Given its uncertain pathogenic role, Prevotella species are not typically targeted by these treatment regimens [62]. Despite this, AMR rates in Prevotella are trending upwards [61], possibly due to bystander selection. To examine this phenomenon, we determined AMR profiles for all cultivable Prevotella strains (n=27) using disc diffusion against 11 antibiotics commonly used to treat lung infections [15, 61], or which have known activity against anaerobic taxa [48]. AMR (AZM, CAZ, CLI, MZ, TOB) or reduced susceptibility (AMC, AZM, CAZ, DOX, MEM) was observed in at least one strain, whereas all were susceptible towards CHL, TZP and IPM, an observation supported by previous studies [48, 61, 63]. Contemporaneous antibiotic treatment did not fully correlate with strain phenotypes, with participants SCHI0011 and SCHI0027 (receiving CAZ) and SCHI0028 (receiving MEM) harbouring both antimicrobial-sensitive and reduced-susceptibility/AMR strains (Table 2). Factors such as biofilm-associated antibiotic tolerance or cooperative antibiotic inactivation from other microbiota [64] may explain the persistence of antimicrobial-sensitive Prevotella in participants undergoing otherwise effective treatments.

Reflecting much greater lifetime antimicrobial use in the CF cohort [65], the 18 tested CF strains had much higher AMR incidence (57% vs. 8%) and AMR gene presence (83% vs. 35%) compared with COPD strains, and this rate increased to 100% (69% for COPD) when including strains with reduced susceptibility towards one or more antibiotics (Table 2). In addition, almost all CF participants were undergoing antimicrobial treatment with at least two different antibiotic classes at the time of sample collection, vs. almost no antibiotic use in the COPD participants (Table S1). One strain, CF isolate P. histicola SCHI0009.S.6, could be classed as multidrug-resistant due to exhibiting AMR towards three antibiotic classes [66] – β-lactams, lincosamides and imidazoles – along with reduced susceptibility towards the tetracycline-class antibiotic, DOX (Table 2). Our findings confirm bystander AMR.
Fig. 3. Maximum-parsimony within-species phylogenomic reconstruction of *P. denticola*, *P. histicola*, *P. melaninogenica*, *P. nanceiensis* and *P. salivae*. Strains identified from COPD and CF specimens from this study are labelled with the prefix 'SCHI'; the remaining strains are public genomes. Coloured branch labels represent the number of SNP differences observed within individual participants, asterisks indicate branches with <80% bootstrap support, and incorrectly speciated public genomes are denoted by single quotes. CI, consistency index. Trees were rooted according to the most ancestral taxon for each species (Fig. S1).
Table 2. Disc diffusion and antimicrobial resistance gene results for genome-sequenced *Prevotella* isolates from cystic fibrosis (CF) or chronic obstructive pulmonary disease (COPD) respiratory secretions, and antibiotic treatment at time of isolate collection

| Strain ID       | *Prevotella* sp.*          | antibiotic disc diffusion diameter (mm) by antibiotic class | cfxA allele | Antibiotic treatment† |
|-----------------|---------------------------|-------------------------------------------------------------|-------------|------------------------|
|                 |                           | Macrolide-lincosamides | Tetra- cyclines | Other | β-Lactams |             |             |
|                 |                           | AZM | CLI | DOX | CHL | MZ | TOB | AMC | CAZ | TZP | IPM | MEM |             |             |
| CF-derived isolates |                           |     |     |     |     |     |     |     |     |     |     |     |             |             |
| SCHI0006.S.13   | *P. histicola*            | 50  | 60  | 24‡ |     | 42  | 50  | 6   | 70  | 52  | 64  | 60  | 58    | Neg  | Nil  |
| SCHI0009.S.5    | *P. melaninogenica*       | 6§  | 6§  | 22‡ |     | 34  | 38  | 6   | 30  | 30  | 50  | 60  | 46    | Neg  | FOE, TOB |
| SCHI0009.S.6    | *P. histicola*            | 6§  | 6§  | 16‡ |     | 32  | 6   | 6   | 50  | 40  | 48  | 60  | 44    | Neg  | FOE, TOB |
| SCHI0010.S.3    | *P. nanceiensis*          | NT§ | NT§ | NT‡ | NT  | NT  | NT  | NT  | NT  | NT  | NT  | NT  | cfxA3 | CAZ, TOB |
| SCHI0011.S.12   | *P. nanceiensis*          | 32  | 40  | 14‡ |     | 34  | 6   | 6   | 20  | 6   | 44  | 56  | 46    | cfxA3 | CAZ, TOB |
| SCHI0011.S.13   | *P. jejunii*              | 46  | 48  | 20‡ |     | 34  | 46  | 6   | 34  | 32  | 52  | 62  | 40    | Neg  | CAZ, TOB |
| SCHI0018.S.9    | *P. salivae*              | NT§ | NT§ | NT‡ | NT  | NT  | NT  | NT  | NT  | NT  | NT  | NT  | cfxA3 | CAZ, TZP, TOB |
| SCHI0021.S.9    | *P. denticola*            | 6§  | 6§  | 24‡ |     | 34  | 58  | 6   | 24  | 10  | 46  | 54  | 44    | cfxA4 | CAZ, TOB |
| SCHI0027.S.6    | *P. melaninogenica*       | 26  | 52  | 44  |     | 32  | 42  | 6   | 24  | 14  | 42  | 54  | 46    | Neg  | CAZ, TOB |
| SCHI0027.S.7    | *P. histicola*            | 6§  | 6§  | 50  |     | 34  | 40  | 6   | 14  | 10  | 48  | 50  | 46    | cfxA3 | CAZ, TOB |
| SCHI0027.S.9    | *P. melaninogenica*       | 42‡ | 34§ | 40  |     | 44  | 6   | 6   | 48  | 40  | 52  | 64  | 50    | cfxA3 | CAZ, TOB |
| SCHI0027.S.11   | *P. melaninogenica*       | NT§ | NT§ | NT‡ | NT  | NT  | NT  | NT  | NT  | NT  | NT  | NT  | NT    | cfxA3 | CAZ, TOB |
| SCHI0027.S.12   | *P. denticola*            | 8§  | 6§  | 20‡ |     | 34  | 44  | 6   | 10  | 6   | 38  | 46  | 38    | cfxA3 | CAZ, TOB |
| SCHI0027.S.13   | *P. melaninogenia*        | NT§ | NT§ | NT‡ | NT  | NT  | NT  | NT  | NT  | NT  | NT  | NT  | NT    | cfxA3 | CAZ, TOB |
| SCHI0027.S.14   | *P. denticola*            | 14‡ | 6§  | 56  |     | 42  | 50  | 6   | 14  | 8   | 48  | 48  | 40    | cfxA3 | CAZ, TOB |
| SCHI0028.S.1    | *P. histicola*            | 18  | 54  | 14‡ |     | 38  | 40  | 6   | 50  | 32  | 44  | 60  | 26    | cfxA2 | MEM, TOB |
| SCHI0028.S.4    | *P. histicola*            | 20  | 64  | 24‡ |     | 48  | 44  | 6   | 26  | 34  | 56  | 62  | 40    | cfxA2 | MEM, TOB |
| SCHI0028.S.5    | *P. nigrescens*           | 10§ | 50§ | 30‡ |     | 50  | 60  | 6   | 36  | 24  | 50  | 56  | 50    | cfxA2 | MEM, TOB |
| COPD-derived isolates |                           |     |     |     |     |     |     |     |     |     |     |     |     |             |             |
| SCHI0034.S.5    | *P. histicola*            | 52  | 70  | 64  |     | 50  | 60  | 6   | 66  | 58  | 66  | 60  | 50    | Neg  | Nil  |
| SCHI0034.S.6    | *P. histicola*            | 44  | 60  | 58  |     | 42  | 50  | 6   | 58  | 50  | 58  | 58  | 50    | Neg  | Nil  |
| SCHI0034.S.7    | *P. melaninogenica*       | 40  | 48  | 12‡ |     | 34  | 38  | 6   | 48  | 20  | 46  | 52  | 54    | cfxA3 | Nil  |
| SCHI0034.S.8    | *P. salivae*              | 38  | 54  | 20‡ |     | 36  | 46  | 6   | 50  | 20  | 50  | 54  | 48    | Neg  | Nil  |
| SCHI0034.S.9    | *P. melaninogenica*       | NT  | NT  | NT  | NT  | NT  | NT  | NT  | NT  | NT  | NT  | NT  | cfxA3 | Nil  |

Continued
| Strain ID      | Prevotella sp.* | Antibiotic disc diffusion diameter (mm) by antibiotic class | cfxA allele | Antibiotic treatment† |
|----------------|-----------------|-------------------------------------------------------------|-------------|-----------------------|
|                |                 | Macrolide-lincosamides | Tetra-cyclines | Other | β-Lactams |                |                |                |
|                |                 | AZM | CLI | DOX | CHL | MZ | TOB | AMC | CAZ | TZP | IPM | MEM |                |                |                |
| SCHI0034.S.10  | *P. lacticola*   | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT | Neg | Nil            |
| SCHI0034.S.11  | *P. salivae*     | 46 | 50 | 20† | 36 | 44 | 6  | 48 | 26 | 48 | 52 | 52 | Neg | Nil            |
| SCHI0042.S.4   | *P. dentocila*   | 38 | 46 | 24‡ | 36 | 46 | 6  | 18 | 14 | 44 | 50 | 42 | cfxA2, cfxA5  | AMX            |
| SCHI0042.S.5   | *P. naceiensis*  | 30 | 36 | 26‡ | 34 | 6  | 6  | 14 | 12 | 36 | 52 | 52 | cfxA3          | AMX            |
| SCHI0043.S.1   | *P. melaninogenica* | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT | Neg | Nil            |
| SCHI0043.S.2   | *P. melaninogenica* | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT | Neg | Nil            |
| SCHI0043.S.3   | *P. melaninogenica* | 36 | 44 | 54 | 36 | 48 | 6  | 50 | 34 | 50 | 58 | 50 | Neg | Nil            |
| SCHI0044.S.1   | *P. melaninogenica* | 34 | 56 | 60 | 42 | 48 | 6  | 30 | 24 | 56 | 58 | 52 | Neg | Nil            |
| SCHI0047.S.2   | *P. melaninogenica* | 40 | 48 | 24‡ | 32 | 48 | 6  | 18 | 12 | 50 | 50 | 46 | cfxA2         | Nil            |
| SCHI0047.S.3   | *P. salivae*     | 40 | 48 | 24‡ | 32 | 48 | 6  | 18 | 12 | 50 | 50 | 46 | Neg | Nil            |
| SCHI0047.S.4   | *P. buccae*      | 46 | 58 | 54 | 42 | 52 | 6  | 52 | 38 | 58 | 56 | 50 | Neg | Nil            |
| SCHI0049.S.1   | *P. melaninogenica* | 44 | 58 | 58 | 44 | 50 | 6  | 24 | 20 | 58 | 60 | 52 | cfxA3         | Nil            |
| LMG 28911 (type strain) | *P. melaninogenica* | 40 | 54 | 50 | 36 | 46 | 6  | 50 | 50 | 54 | 52 | 38 | Unknown       | Unknown        |

Dark grey-shaded cells represent definitive antimicrobial resistance (i.e. growth right up to the disc), light grey-shaded cells reflect reduced susceptibility (≤30 mm diameter) and unshaded cells represent probable sensitivity (>30 mm diameter).

*As determined from whole-genome sequence analysis.
†At the time of clinical specimen collection from which the isolate was derived.
‡Encodes tetQ, which is associated with decreased susceptibility/resistance towards tetracycline-class antibiotics [71, 73] such as DOX.
§Encodes ermF, which confers resistance towards erythromycin [73].
AMC, amoxicillin-clavulanate; AMX, amoxicillin; AZM, azithromycin; CAZ, ceftazidime; CHL, chloramphenicol; CLI, clindamycin; DOX, doxycycline; FOF, fosfomycin; IPM, imipenem; MEM, meropenem; MZ, metronidazole; Neg, negative; NT, not tested for antimicrobial sensitivity; TZP, piperacillin-tazobactam; TOB, tobramycin.
selection in off-target *Prevotella* as a direct result of heavy antimicrobial use in CF (and to a much lesser extent, COPD), which may have ramifications for *Prevotella* persistence as a potential driver of disease pathogenesis.

TOB was the only antibiotic tested that showed AMR in all tested isolates, including the type strain, *P. melaninogenica* LMG 28911 (Table 2). This finding concurs with prior work reporting 100% TOB resistance among 157 *Prevotella* isolates [61]. A CF microbiome study also found that *Prevotella* abundance was largely unchanged upon TOB treatment [67]. These collective findings indicate that all respiratory *Prevotella* species are intrinsically resistant to TOB. Notably, we observed that the median relative *Prevotella* abundance according to metataxonomics was quite different between CF (9.6%) vs. COPD (0.6%) specimens (Table S3). Although the basis of this higher relative *Prevotella* abundance in CF is unknown, one possibility is that most of our CF participants were receiving TOB at the time of sample collection (Table 2 and S1), whereas no COPD participant was receiving this antibiotic. The predominance of *Prevotella* species in the CF airways might thus be attributed to much more frequent TOB use in this cohort [68–70]. Although not assessed in this study, adding TOB to selective media may improve *Prevotella* recovery rates from respiratory specimens by suppressing growth of other taxa. After TOB, CLI resistance was most common (6/14 CF isolates), followed by AZM (4/14 CF isolates), MZ (1/13 COPD and 3/14 CF isolates) and CAZ (2/14 CF isolates). Decreased susceptibility towards AMC, CAZ and DOX was common in both CF and COPD isolates; however, only CF isolates exhibited decreased AZM susceptibility (6/14 isolates). These results provide further evidence of bystander selection in *Prevotella* species, with this effect especially noticeable in CF-derived isolates.

AMR genes represent a major concern in infection control as they can rapidly transfer AMR among different genera and species. To determine AMR gene potential, CARD analysis was performed on the 35 CF-COPD *Prevotella* genomes and used to correlate horizontally acquired AMR-conferring genes with AMR/decreased-susceptibility phenotypes. Consistent with their higher AMR rates, CF isolates demonstrated greater prevalence of AMR-conferring genes compared with COPD isolates (Table 2). Strikingly, 67% CF strains encoded *ermF*, a horizontally acquired gene that confers resistance towards macrolide, lincosamide and streptogramin-class antibiotics such as AZM and CLI [48, 63, 71]. In contrast, *ermF* was absent in all COPD strains, a somewhat unexpected finding given that COPD participants are frequently given long-term macrolides (e.g. azithromycin, erythromycin) as prophylaxis to reduce exacerbation frequency [72]. None of the CF or COPD participants were receiving these antibiotics at the time of sample collection, suggesting that cross-resistance or prior CF antibiotic treatment may be driving *ermF* acquisition and maintenance in *Prevotella*. *ermF* presence correlated well with AZM and CLI AMR/decreased susceptibility (87 and 75%, respectively). *ermF* rates in our Australian isolates exceed those previously reported (23–68% in UK, USA and Italian isolates from both healthy and diseased participants) [71, 73]. This discrepancy is likely to be due to only respiratory disease-associated isolates being tested in our study; but may also be due to differences in AMR cut-offs between studies, *in vivo* antibiotic exposure levels, and potentially species or strain composition, noting that one study only identified most isolates to the genus level [71].

*tetQ*, which confers resistance to tetracycline-class antibiotics (e.g. DOX) [71, 73], was present in 54% of our strains, and more common in CF-derived strains (67% vs. 41%). This rate is much higher than *tetQ* prevalence reported in UK CF (21%) [71] and
human-derived Dutch (30%) [63] strains. Our \textit{tetQ}-harbouring strains consistently showed much smaller DOX disc diameters (12–30 mm; median 22 mm) compared with \textit{tetQ}-negative strains (40–64 mm; median 54 mm) with 100% correlation between \textit{tetQ} presence and decreased DOX susceptibility (Table 2). A prior study reported that 83% of \textit{tetQ}-positive isolates demonstrated intermediate or full resistance towards tetracycline [71], suggesting that \textit{tetQ} is a reliable marker of reduced susceptibility towards tetracycline-class antibiotics. Taken together, these results confirm that \textit{tetQ} presence robustly confers decreased DOX susceptibility in \textit{Prevotella} species. Although our dataset is small, we propose \textit{Prevotella} species DOX disc diameters of ≥40 mm to denote strains lacking \textit{tetQ}, and ≤30 mm to denote strains that may be harbouring \textit{tetQ}, with the caveat that other enigmatic determinants conferring reduced DOX susceptibility (e.g. chromosomal mutations) may be present in lieu of \textit{tetQ}. These criteria also differentiate \textit{Prevotella} species exhibiting decreased DOX susceptibility from DOX-sensitive strains.

The \textit{cfxA}-type β-lactamase gene is the most clinically important AMR mechanism in \textit{Prevotella} species [74] as it confers AMR towards cephemycins [61] and some other β-lactam antibiotics [71], which are commonly used in respiratory infection treatment [61]. Concerningly, \textit{cfxA} is often encoded on mobile elements, meaning that AMR can potentially be transmitted from \textit{Prevotella} species to known pathogenic taxa in the respiratory microbiome [75]. We found \textit{cfxA} alleles 2, 3, 4 and/or 5 in 54% of strains (72% CF and 35% COPD). \textit{cfxA}3 and \textit{cfxA}2 were most common, being present in 37 and 14% strains, respectively. In comparison, a study of UK and USA isolates reported much higher \textit{cfxA} carriage rates (86%), with 29 and 52% of strains encoding \textit{cfxA}3 and \textit{cfxA}2, respectively. Their study also found that \textit{cfxA}3-encoding isolates exhibited significantly higher CAZ resistance levels [71], which we also observed in our \textit{cfxA}3-harbouring strains (median disc diameter=12 mm vs. 32 mm in non-\textit{cfxA}3 strains) (Table 2). In \textit{cfxA}3-encoding strains displaying CAZ sensitivity, reduced \textit{cfxA}3 expression [76] may explain this phenotype, although this was not explored in our study. In addition, we did not test \textit{Prevotella} susceptibility towards cephemycins so were unable to determine whether \textit{cfxA} variants correlated with these β-lactam antibiotics.

MZ resistance was evident in 4/28 tested strains (three CF; one COPD), despite none of the participants receiving nitroimidazoles at the time of sample collection. Other than TOB, MZ was the only antibiotic that exhibited AMR in any of the COPD strains. The \textit{nim} genes, which encode for nitroimidazole reductase enzymes and have previously been associated with MZ resistance in \textit{P. baroniae} [77] and \textit{P. bivia} [78], were not detected in any isolate. Therefore, the basis of MZ resistance in our isolates remains unknown.

Of the eight \textit{Prevotella} species identified in our study, four are conventionally considered dark-pigmented – \textit{P. denticola}, \textit{P. histicola}, \textit{P. melaninogenica} and \textit{P. nigrescens}. Pigmented \textit{Prevotella} reportedly harbour a greater cache of virulence factors and are more commonly associated with infection [48]. However, we found limited phenotypic differences within and between species on non-selective anaerobic blood medium at Day 3 (Fig. 4), with most presenting as convex, shiny, white colonies; only \textit{P. nigrescens}
demonstrated tan pigmentation in the primary streak at this time point (Fig. 4f). In contrast, a dark brown to black pigment was produced by *P. nigrescens* on PVCA by Day 3 (Fig. 5d), but not on selective or non-selective anaerobic media, even by Day 10, with only medium-brown colonies present (Fig. 5b, c). *P. histicola* demonstrated tan-coloured pigmentation on both non-selective anaerobic medium and PVCA, but only after 5 days (Fig. 6), and unlike *P. nigrescens*, did not develop black pigment on PVCA at Days 5 or 10. *P. melaninogenica* reportedly produces a characteristic dark pigment that is commonly associated with the species [79, 80]; yet, no pigmentation was observed in the six *P. melaninogenica* isolates on any medium by Day 10. A probable explanation for this phenomenon is that different strains require different media for pigment production [81]. Collectively, the limited pigmentation observed among *Prevotella* species suggests that phenotypic characteristics alone should not be used for *Prevotella* genus or species identification.

We acknowledge several study limitations. First, the small sample size (43 enrolled participants; 69 samples) and inclusion of only COPD and CF samples make it difficult to generalize our results across a larger cohorts. Nevertheless, the broad agreement of our findings with previous literature [10, 14, 19] demonstrates a reasonable estimation of species diversity in these cohorts. Second, due to non-anaerobic sample handling and storage, non-aerotolerant *Prevotella* species may have been rendered non-viable and thus not recoverable [46]. Future establishment of disc diffusion guidelines in *Prevotella* will enable more accurate assessment of AMR phenotypes in this genus. Third, due to our use of a strict AMR cut-off (i.e. 6 mm), AMR rates in our *Prevotella* are almost certainly underestimated. Fourth, we did not assess healthy airway microbiota due to difficulties associated with obtaining respiratory secretions from healthy participants. Future work should continue to seek strain-level resolution of *Prevotella* strains in CF and COPD airways, including the design of species-specific assays towards commonly isolated and known pathogenic species, assessment of *Prevotella* from healthy airways, and incorporation of higher-resolution molecular technologies such as metagenomics and metatranscriptomics to gain a clearer understanding of *Prevotella* function within complex microbiomes.

**Fig. 6.** Phenotypic comparison of *P. histicola* on non-selective anaerobic blood medium (top) and polyvitaminic-supplemented chocolate agar (bottom) at (a, c) 3 days and (b, d) 5 days.
Co-culture experiments between *Prevotella* species and known respiratory pathogens, such as *Pseudomonas aeruginosa*, would be beneficial for elucidating the role of *Prevotella* in potentiating or abrogating pathogen virulence. Finally, phylogeographic analysis of *Prevotella* genomes may permit a deeper understanding of *Prevotella* species distribution and strain diversity in chronic lung disease globally, and population genomic approaches will yield a better understanding of *Prevotella* origin and capacity for airway-to-airway transmission.

Funding information
This work was funded by Advance Queensland (awards AQRF13016-17R02 and AQRF0362018), the Wishlist Sunshine Coast Hospital Foundation (award 2019-24), and the University of the Sunshine Coast.

Acknowledgements
We thank Tamieka Fraser (University of the Sunshine Coast) for laboratory assistance, Peter Timms (University of the Sunshine Coast) and Laura Sherrard (Queen's University Belfast) for insightful feedback on the manuscript, Tania Duarte (University of Queensland) for helpful discussions about the challenges of *Prevotella* identification using current metagenomic pipelines, and the Belgian Co-ordinated Collection of Micro-organisms (BCCM) for providing type strains.

Conflicts of interest
The authors declare that there are no conflicts of interest.

Ethical statement
Collection and analysis of clinical samples was approved by The Prince Charles Hospital (TPCH) Human Research Ethics Committee (HREC), project IDs HREC/13/QPCH/127 (CF samples) and HREC/2019/QPCH/48013 (COPD samples). Site-specific approvals were obtained for CF recruitment at TPCH, Brisbane, Australia, and COPD recruitment at Sunshine Coast Hospital and Health Service, Sunshine Coast, Australia. All participants provided written consent.

References
1. Sze MA, Hogg JC, Sin DD. Bacterial microbiome of lungs in COPD. *Int J Chron Obstruct Pulmon Dis* 2014;9:229–238.
2. Fenker DE, McDaniel CT, Panmanee W, Panos RJ, Sorscher EJ, *et al.* A comparison between two pathophysiology different yet microbiologically similar lung diseases: cystic fibrosis and chronic obstructive pulmonary disease. *Int J Respir Pulm Med* 2018;5:998.
3. Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. *Lancet* 2007;370:786–796.
4. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. *Clin Microbiol Rev* 2002;15:194–222.
5. Jacobs DM, Pandit U, Sethi S. Acute exacerbations in chronic obstructive pulmonary disease: should we use antibiotics and if so, which ones? *Curr Opin Infect Dis* 2019;32:143–151.
6. Larsen JM. The immune response to *Prevotella* bacteria in chronic inflammatory disease. *Immunology* 2017;151:363–374.
7. Gilpin DF, Nixon KA, Bull M, McGrath SJ, Sherrard L, *et al.* Evidence of persistence of *Prevotella* spp. in the cystic fibrosis lung. *J Med Microbiol* 2017;66:825–832.
8. Ditz B, Christensen S, Rossen J, Brightling C, Kerstjens HAM, *et al.* Sputum microbiome profiling in COPD: beyond singular pathogen detection. *Thorax* 2020;75:338–344.
9. Pattison SH, Rogers GB, Crockard M, Elborn JS, Tunney MM. Molecular detection of CF lung pathogens: current status and future potential. *J Cyst Fibros* 2013;12:194–205.
10. Lee S-W, Kuan C-S, Wu LS-H, Weng JT-Y. Metagenome and metatranscriptome profiling of moderate and severe COPD Sputum in Taiwanese Han Males. *PloS One* 2016;11:e0159066.
11. Muhlebach MS, Hatch JE, Einarrsson GG, McGrath SJ, Gilpin DF, *et al.* Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study. *Eur Respir J* 2018;52:1800242.
12. Amat S, Lantz H, Munyaka PM, Willing BP. *Prevotella in pigs: the positive and negative associations with production and health. Microorganisms* 2020;8:10.
13. Wybo I, Soetens D, De Bel A, Echahidi F, Vancutsem E, *et al.* Species identification of clinical *Prevotella* isolates by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J Clin Microbiol* 2012;50:1415–1418.
14. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, *et al.* Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. *Am J Respir Crit Care Med* 2008;177:995–1001.
15. Cuthbertson L, Walker AW, Oliver AE, Rogers GB, Rivett DW, *et al.* Lung function and microbiota diversity in cystic fibrosis. *Microbiome* 2020;8:45.
16. Han MK, Huang YJ, Lipuma JJ, Boushey HA, Boucher RC, *et al.* Significance of the microbiome in obstructive lung disease. *Thorax* 2012;67:456–463.
17. Wang Z, Maschera B, Lea S, Kolsum U, Michalovich D, *et al.* Airway host-microbiome interactions in chronic obstructive pulmonary disease. *Respir Res* 2019;20:113.
18. Mirković B, Murray MA, Lavelle GM, Molloy K, Azim AA, *et al.* The role of short-chain fatty acids, produced by anaerobic bacteria, in the cystic fibrosis airway. *Am J Respir Crit Care Med* 2015;192:1314–1324.
19. Field TR, Sibley CD, Parkins MD, Rabin HR, Surette MG. The genus *Prevotella* in cystic fibrosis airways. *Anaerobe* 2010;16:337–344.
20. Ulrich M, Beer I, Braitemaier P, Dierkes M, Kummer F, *et al.* Relative contribution of *Prevotella* intermedia and *Pseudomonas aeruginosa* to lung pathology in airways of patients with cystic fibrosis. *Thorax* 2010;65:978–984.
21. Jorth P, Ehsan Z, Rezayat A, Caldwell E, Pope C, *et al.* Direct lung sampling indicates that established pathogens dominate early infections in children with cystic fibrosis. *Cell Rep* 2019;27:1190–1204.
22. Zemanick ET, Wagner BD, Sagel SD, Stevens MJ, Accurso FJ, *et al.* Reliability of quantitative real-time PCR for bacterial detection in cystic fibrosis airway specimens. *PloS One* 2010;5:e15101.
23. O’Neill K, Bradley JM, Johnston E, McGrath S, Mcleavey L, *et al.* Reduced bacterial colony count of anaerobic bacteria is associated with a worsening in lung clearance index and inflammation in cystic fibrosis. *PloS One* 2015;10:e0126980.
24. Einarrsson GG, Zhao J, LiPuma JJ, Downey DG, Tunney MM, *et al.* Community analysis and co-occurrence patterns in airway microbial communities during health and disease. *ERJ Open Res* 2019;5:00128-2017.
25. Wang Z, Liu H, Wang F, Yang Y, Wang X, *et al.* A refined view of airway microbiome in chronic obstructive pulmonary disease at species and strain-levels. *Front Microbiol* 2020;11:1758.
26. Human Microbiome Jumpstart Reference Strains Consortium, Nelson KE, Weinstock GM, Highlander SK, Worley KC, et al. A catalog of reference genomes from the human microbiome. Science 2010;328:994–999.

27. Gupta VK, Chaudhari NM, Iskepalii S, Dutta C. Divergences in gene repertoire among the reference Prevotella genomes derived from distinct body sites of humans. BMC Genomics 2015;16:153.

28. Zhang Y, Zhen M, Zhan Y, Song Y, Zhang Q, et al. Population-genomic insights into variation:Genomic Insights into Variation in Prevotella intermedius and Prevotella nigrescens isolates and its association with periodontal disulates and Its Association with Periodontal Disease. Front Cell Infect Microbiol 2017;7:609.

29. Tett A, Huang KD, Asnicar F, Fehlner-Peach H, Pasolli E, et al. The Prevotella capri complex comprises four distinct clades underrepresented in westernized populations. Cell Host Microbe 2019;26:666–679.

30. de Lamballerie X, Zandotti C, Vignoli C, Bollet C, de Micco P. A one-step microbial DNA extraction method using “Chelex 100” suitable for gene amplification. Res Microbiol 1992;143:785–790.

31. Triant DA, Whitehead A. Simultaneous extraction of high-quality RNA and DNA from small tissue samples. J Hered 2009;100:246–250.

32. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990;215:403–410.

33. Klaassen CHW, Jeunin MAF, Prinsen CFM, Ruers TJM, Tan ACITL, et al. Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer. Clin Chem 2003;49:1185–1187.

34. Nadkarni MA, Martin FE, Jacques NA, Hunter N. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology 2002;148:257–266.

35. Price EP, Dale JL, Cook JM, Sarovich DS, Seymour ML, et al. Development and validation of Burkholderia pseudomallei-specific real-time PCR assays for clinical, environmental or forensic detection applications. PLoS One 2012;7:e37723.

36. Hudzicki J. Kirby-Bauer Disk Diffusion Susceptibility Test Protocol: 2016. https://asm.org/Protocols/Kirby-Bauer-Disk-Diffusion-Susceptibility-Test-Pro

37. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 2012;19:455–477.

38. Jolley KA, Bliss CM, Bennett JS, Bratcher HB, Brehony C, et al. Ribosomal multilocus sequence typing: universal characterization of bacteria from domain to strain. Microbiology (Reading) 2012;158:1005–1015.

39. Sarovich DS, Price EP. SPANDx: a genomics pipeline for comparative analysis of large haploid whole genome re-sequencing datasets. BMC Res Notes 2014;7:618.

40. Li H. Aligning sequence reads, clone sequences and assembly contigs with bwa-mem. arXiv 2013:1303.3997.

41. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, et al. ClustalW and ClustalX version 2.0. Bioinformatics 2007;23:2947–2948.

42. Huang W, Li L, Myers JR, Marth GT. ART: a next-generation sequencing read simulator. Bioinformatics 2012;28:593–594.

43. Bolger AM, Lohse M, Usadel B. Trimomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 2014;30:2112–2120.

44. Price EP, Vibeorg LT, Kidd TJ, Bell SC, Currie BJ, et al. Transcriptomic analysis of longitudinal Burkholderia pseudomallei infected the cystic fibrosis lung. Microb Genom 2018;4:e000194.

45. Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, et al. CARD 2020: antibiotic resistance surveillance with the comprehensive antibiotic resistance database. Nucleic Acids Res 2020;68:D517–D525.

46. Silva VL, Carvalho MAR, Nicoli JR, Farias LM. Aerotolerance of human clinical isolates of Prevotella spp. J Appl Microbiol 2003;94:701–707.

47. Aizaz A, Currie BJ, Mayo M, Sarovich DS, Price EP. Comparative genomics confirms a rare melioidosis human-to-human transmission event and reveals incorrect phylogenomic reconstruction due to plasmolomy. Microb Genom 2020;6:e000326.

48. Xie Y, Chen J, He J, Xiao X, Xu M, et al. Antimicrobial resistance and prevalence of resistance genes of obligate anaerobes isolated from periodontal abscesses. J Periodontol 2014;85:327–334.

49. Goddard AF, Staudinger BJ, Dowd SE, Joshi-Datar A, Wolcott RD, et al. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. Proc Natl Acad Sci U S A 2012;109:13769–13774.

50. Pragman AA, Lyu T, Bailer JA, Gould TJ, Kelly RF, et al. The lung microbiota of mild and moderate chronic obstructive pulmonary disease. Microbiome 2018:6:7.

51. Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Falkowski NR, et al. Bacterial topography of the healthy human lower respiratory tract. mBio 2017;8:e02287–16.

52. Bassis CM, Erb-Downward JR, Dickson RP, Freeman CM, Schmidt TM, et al. Analysis of the upper respiratory tract microbial biotas as the source of the lung and gastric microbiotas in healthy individuals. mBio 2015;6:e00037.

53. Larsen JM, Steen-Jensen DB, Laursen JM, Søndergaard JN, Musavian HS, et al. Divergent pro-inflammatory profile of human dendritic cells in response to commensal and pathogenic bacteria associated with the airway microbiota. PLoS One 2012;7:e31976.

54. Hedberg ME, Israelsson A, Moore ERB, Svensson-Stadler L, Wai SN, et al. Prevotella jejuni sp. nov., isolated from the small intestine of a child with coeliac disease. Int J Syst Evol Microbiol 2013;63:4218–4223.

55. Gürsoy M, Harju I, Matomäki J, Bryk A, Könönen E. Performance of MALDI-TOF MS for identification of oral Prevotella species. Anaerobe. 2017;47:89–93.

56. Enauf R, Prevel R, Cirillo E, Beauflis F, Wierès G, et al. The gut-lung axis in health and respiratory diseases: a place for inter-organ and inter-domain crosstalks. Front Cell Infect Microbiol 2020;10:10.

57. Bertelsen A, Elborn SJ, Schock BC. Toll-like Receptor signalling by Prevotella histicola activates alternative NF-κB signalling in Cystic Fibrosis bronchial epithelial cells compared to P. aeruginosa. PLoS One 2020;15:e0235803.

58. Di Lorenzo F, Silipo A, Matier T, Hanuszkiewicz A, Elborn JS, et al. Prevotella denticola lippopolysaccharide from a cystic fibrosis isoleus possesses a unique chemical structure. Eur J Org Chem 2016;2016:1732–1738.

59. Yanagisawa M, Kuriyama T, Williams DW, Nakagawa K, Karasawa T. Proteinase activity of Prevotella spp. associated with oral purulent infection. Curr Microbiol 2006;52:375–378.

60. Alauzet C, Marchand H, Lozniewski A. New insights into Prevotella diversity and medical microbiology. Future Microbiol 2010;5:1695–1718.

61. Sherrard LJ, Graham KA, McGrath SJ, McIlreavey L, Hatch J, et al. Antibiotic resistance in Prevotella species isolated from patients with cystic fibrosis. J Antimicrob Chemother 2013,68:2369–2374.

62. Brill SE, Law M, El-Emir E, Allinson JP, James P, et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax 2015;70:930–938.

63. Veloo ACM, Baas WH, Haan FJ, Coco J, Rosven JW. Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect 2019;25:1156.

64. Bottery MJ, Pitchford JW, Friman VP. Ecology and evolution of antimicrobial resistance in bacterial communities. ISME J 2013;15:939–948.

65. Sherrard LJ, Tunney MM, Elborn JS. Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet 2014;384:370–373.

66. Hahn A, Burrell A, Fanous H, Chaney H, Sami I, et al. Antibiotic multidrug resistance in the cystic fibrosis airway microbiome is associated with decreased diversity. Heliyon 2018;4:e00795.
67. Nelson MT, Wolter DJ, Eng A, Weiss EJ, Vo AT, et al. Maintenance tobramycin primarily affects untargeted bacteria in the CF sputum microbiome. Thorax 2020;75:780–790.

68. Bittar F, Richet H, Dubus J-C, Reynaud-Gaubert M, Stremler N, et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 2008;3:e2908.

69. Shakil S, Khan R, Zarrilli R, Khan AU. Aminoglycosides versus bacteria—a description of the action, resistance mechanism, and nosocomial battleground. J Biomed Sci 2008;15:5–14.

70. Thornton CS, Surette MG. Potential contributions of anaerobes in cystic fibrosis airways. J Clin Microbiol 2021;59:e01813-19.

71. Sherrard LJ, McGrath SJ, McIlreavey L, et al. Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in Prevotella isolated from cystic fibrosis (CF) and non-CF patients. J Antimicrob Chemother 2014;69:2690–2698.

72. Sherrard LJ, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, et al. Production of extended-spectrum β-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota. Int J Antimicrob Agents 2016;47:140–145.

73. Sherrard LJ, Sutherland S, Schaible B, Graham KA, McGrath SJ, McIlreavey L, et al. Production of extended-spectrum β-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota. Int J Antimicrob Agents 2016;47:140–145.

74. Jolivet-Gougeon A, Tamanai-Shacoori Z, Desbordes L, Burggraeve N, Cormier M, et al. Genetic analysis of an ambler class A extended-spectrum beta-lactamase from Capnocytophaga ochracea. J Clin Microbiol 2004;42:888–890.

75. Alauzet C, Mory F, Teysier C, Hallage H, Carlier JP, et al. Metronidazole resistance in Prevotella spp. and description of a new nim gene in Prevotella baroniae. Antimicrob Agents Chemother 2010;54:60–64.

76. Veloo ACM, Chlebowicz M, Winter HLJ, Bathoorn D, Rossen JWA. Three metronidazole-resistant Prevotella bivia strains harbour a mobile element, encoding a novel nim gene, nimK, and an efflux small MDR transporter. J Antimicrob Chemother 2018;73:2687–2690.

77. Zhou X, Li Y. Subgingival microbes: from healthy microflora to disease. Atlas of Oral Microbiology. Elsevier, 2015.

78. Finegold SM. Anaerobic Gram-negative bacilli (Chapter 20. In: Baron S (eds). Medical Microbiology, 4th edn. Galveston, TX: University of Texas Medical Branch at Galveston; 1996.)

---

Five reasons to publish your next article with a Microbiology Society journal

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at microbiologyresearch.org.